Shouyao Holdings (Beijing) Co. Ltd. engages in the clinical research stage of the innovative drug business. The company is mainly involved in the research and development of drugs covering non-small cell lung cancer, lymphoma, hepatocellular carcinoma, pancreatic cancer, thyroid cancer, ovarian cancer, leukemia, key tumor indications, and type 2 diabetes. It offers a collection of AI drug design, medicinal chemistry, biology, pharmacokinetics, toxicology, pharmaceutical research, clinical research, operation management, and quality management. The company was founded on April 19, 2016 and is headquartered in Beijing, China.